Q3 biotech roundup: The 2024 turnaround sputters into a critical Q4 finale

John Carroll

Editor & Founder

Some, though certainly not all, chief indicators of biotech business activity are pointed shakily north as we head into a critical Q4. But biotech shows …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

Q3 biotech roundup: The 2024 turnaround sputters into a critical Q4 finale

John Carroll

Editor & Founder

This article is available only to Premium subscribers

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Starboard takes activist stake in J&J consumer spinout Kenvue

Former Karuna crew quickly assembles $225M for next neuro bet at Seaport

Novo declares Phase 3 cardiac outcomes trial win for oral GLP-1

Biden administration calls for expanded contraception coverage

Lilly files more lawsuits over sales of copycat Zepbound

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Q3 biotech roundup: The 2024 turn­around sput­ters in­to a crit­i­cal Q4 fi­nale

Editor & Founder

This article is available only to Premium subscribers

Viridian Therapeutics

Waltham, MA, USA

Q3 biotech roundup: The 2024 turnaround sputters into a critical Q4 finale